Recruiting Clinical Trials

Displaying 21 - 30 of 238 result(s)
Study Title Condition Phase Location
A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate ... Osteoarthritis (OA) Phase 2
  • Country: 
    Austria
  • Country: 
    Netherlands
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in M ... Extensive Stage Small Cell Lung Cancer Phase 1
  • Country: 
    France
  • Country: 
    Spain
A Randomized, Four-arm, Canakinumab Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Os ... Knee Osteoarthritis Phase 2
  • Country: 
    United States
  • Country: 
    China
  • Country: 
    Czech Republic
  • Country: 
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis) Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis Not Given
  • Country: 
    Japan
A Randomized, Open-label, Two Arm, Parallel Group, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy Glomerulonephritis, Membranous Phase 2
  • Country: 
    United States
  • Country: 
    China
  • Country: 
    France
  • Country: 
A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) in Patients With Relapsing Multiple Sclerosis [AIOLOS] Relapsing Multiple Sclerosis Not Given
  • Country: 
    Germany
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticostero ... Lupus Nephritis Phase 2
  • Country: 
    United States
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Neph ... Lupus Nephritis Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Br ... Asthma Phase 2
  • Country: 
    Bulgaria
  • Country: 
    Hungary
  • Country: 
    Poland
  • Country: 
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors Mesothelioma Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Canada
  • Country: